908 Devices’ (MASS) “Sell (E+)” Rating Reiterated at Weiss Ratings

908 Devices (NASDAQ:MASS)‘s stock had its “sell (e+)” rating reiterated by investment analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, Stephens reiterated an “overweight” rating and issued a $6.00 price target on shares of 908 Devices in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Stock Up 8.9 %

MASS opened at $4.53 on Friday. The stock’s fifty day moving average is $2.91 and its two-hundred day moving average is $2.92. The company has a market capitalization of $160.04 million, a P/E ratio of -2.56 and a beta of 0.99. 908 Devices has a 52 week low of $1.81 and a 52 week high of $7.56.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. boosted its position in shares of 908 Devices by 6.3% in the 4th quarter. AWM Investment Company Inc. now owns 1,673,924 shares of the company’s stock worth $3,683,000 after purchasing an additional 99,594 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of 908 Devices by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 581,300 shares of the company’s stock worth $1,279,000 after purchasing an additional 13,512 shares in the last quarter. State Street Corp boosted its position in shares of 908 Devices by 1.2% in the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock worth $1,662,000 after purchasing an additional 5,704 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of 908 Devices by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock worth $765,000 after purchasing an additional 28,015 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of 908 Devices by 7.5% in the 4th quarter. Northern Trust Corp now owns 200,764 shares of the company’s stock worth $442,000 after purchasing an additional 14,087 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.